Prognostic and predictive factors in breast cancer

Cancer Treatment Reviews

Volumn 27, Issue 3, 2001, Pages 137-142

  Bundred, N J ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTOR; ESTROGEN RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; DISEASE DURATION; EARLY CANCER; FEMALE; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MASTECTOMY; POSTMENOPAUSE; PREDICTION; PREMENOPAUSE; PROGNOSIS; UNITED KINGDOM;

EID: 0035024276     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2000.0207     Document Type: Article

References (32)

1. Fisher B., Redmond C. Lumpectomy for breast cancer: an update of the NSABP experience. J Natl Cancer Inst. 11:1992;7-13.
2. Van Dongen J. A., Bartelink H., Fentiman T. S. Randomised clinical trial to assess the value of breast conserving therapy in Stage I and Stage II breast cancer. J Natl Cancer Inst. 11:1992;15-18.
3. Lancet. 351:1998;1451.
4. CA Cancer J Clin. 48:1998;83-89.
5. Axelsson C. K., Mouridsen H. T., Zedeler K. Axillary dissection of level 1 and II nodes is important in breast cancer classification. Eur J Cancer. 28A:1992;1415-1418.
6. Richards M. A., Smith I. E. ABC of breast diseases. Br Med J. 309:1994;1363-1366.
7. Lancet. 352:1998;930-938.
8. Saarto T., Blomquist C., Valimaki M., Makela P., Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomised study in premenopausal breast cancer patients. J Clin Oncol. 15:1997;1341-1347.
9. Powles T. J., Hickish T., Kanis J. A., Tidy A., Ashley S. Effect of tamoxifen on bone mineral density measured by dual energy X-ray. J Clin Oncol. 14:1996;78-84.
10. McGuire W. L. Breast Cancer Prognostic Factors Evaluation Guidelines. J Natl Cancer Inst. 83:1991;154-155.
11. Fisher B., Bauer M. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer: an NSABP update. Cancer. 52:1983;1551.
12. Galea M. H., Blamey R. W., Elston C. E. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 22:1992;207-211.
13. Silvestrini R., Daidone M. G., Luisi A. Biologic and clinicopathologic factors as indicators of specific relapse types in node negative breast cancer. J Clin Oncol. 13:1995;697-704.
14. Todd J. H., Dowle C., Williams M. R. Confirmation of a prognostic index in primary breast cancer. Br J Cancer. 56:1987;489-492.
15. Nixon A. J., Neuberg D., Hayes D. F. Relationship of patient age to pathological features of the tumour and prognosis for patients with Stage I or II breast cancer. J Clin Oncol. 12:1994;888.
16. De la Rochefordiere A., Asselain B., Campana F. Age as a prognostic factor in premenopausal breast cancer. Lancet. 341:1993;1039-1043.
17. Ravdin P. M., Green S., Melink-Dorr T. Prognostic significance of progesterone receptor levels in oestrogen receptor positive patients with metastatic breast cancer treated with tamoxifen. Results of a prospective Southwest Oncology Group Study. J Clin Oncol. 10:1992;1284-1291.
18. Tubiana M., Pejovic M. H., Koscielny S. Growth rate, kinetics of tumour cell proliferation and long term outcome in human breast cancer. Int J Cancer. 44:1989;17-22.
19. Gasparini G., Boracchi P., Verderio P., Bevilacqua P. Cell kinetics in human breast cancer: comparison between the prognostic value of cytofluorinetic S-phase fraction and that of the antibodies to Ki67 and PCNA antigens. Int J Cancer. 57:1994;822-829.
20. Brown R. W., Allred D. C., Clark G. M. Prognostic value of Ki67 compared to S-phase fraction in axillary node negative breast cancer. Clin Cancer Res. 2:1996;585-592.
21. Gaglia P., Bemardi N., Venesio T. Cell proliferation of breast cancer evaluated by anti Brd-U and anti Ki67 antibodies; its prognostic value on short term recurrences. Eur J Cancer. 29A:1994;1509-1513.
22. Mason S., Gullick W. J. Type 1 growth factor receptor: an overview of receptor developments. The Breast. 4:1995;11-18.
23. Sainsbury J., Farndon J., Sherbert G., Harris A. Epidermal growth factor receptors and oestrogen receptors in human breast cancer. Lancet. i:1985;364-366.
24. i67immunostaining in breast cancer and hormone sensitivity. Eur J Cancer. 29A:1993;1018-1023.
25. Slamon D., Leyland Jones B., Shak S. Addition of Herceptin to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity, a randomised, multinational controlled phase III trial. Proc ASCO. 17:1998;A377.
26. Bobrow L. G., Happerfield L. C., Gregory W. M. Ductal carcinoma in-situ: assessment of necrosis in nuclear morphology and their association with biological markers. J Pathol. 176:1995;333-341.
27. Ross J. H., Fletcher J. A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 16:1998;413-426.
28. Bianco A. R., De Laurentis M., Carlomagno C. 20 year update of the Naples Gun trial of adjuvant breast cancer therapy: evidence of interaction between c-erb-B2 expression and tamoxifen efficacy. Proc Am Soc Clin Oncol. 17:1998;97a.
29. Muss H. B. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 330:1994;1260-1266.
30. Paik S., Bryant J., Park C. erB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. JNH Cancer Inst. 90:1998;1361-1370.
31. Thor A. D., Berry A. D. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 90:1998;1346-1360.
32. Ravdin P. M., Green S., Albain V. Initial report of the SWOG biological correlatine study of CerbB2 expression as a predictor of outcome in a trial comparing adjuvant CAFT with Tamoxifen (J) alone. Proc Am Soc Clin Oncol. 17:1998.